Director Elisabeth Bjork buys 10,000 Rocket Pharmaceuticals (RCKT) shares

Rhea-AI Filing Summary

Rocket Pharmaceuticals director Elisabeth Bjork reported buying 10,000 shares of common stock on January 2, 2026 at $3.44 per share. After this purchase, she beneficially owned 50,000 shares in total.

The total includes 30,000 restricted stock units that convert into common stock on a one-for-one basis and are scheduled to vest in full on June 18, 2026. The filing indicates the shares are held directly rather than through another entity.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bjork Elisabeth

(Last) (First) (Middle)

C/O ROCKET PHARMACEUTICALS, INC.

9 CEDARBROOK DRIVE

(Street)

CRANBURY NJ 08512

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ROCKET PHARMACEUTICALS, INC. [ RCKT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock(1)	01/02/2026		P		10,000	A	$3.44	50,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Includes 30,000 restricted stock units ("RSUs") that convert to common stock on a one-for-one basis and vest in full on June 18, 2026.

	/s/ Martin Wilson, as attorney-in-fact for Elisabeth Bjork	01/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Rocket Pharmaceuticals (RCKT) report for Elisabeth Bjork?

Director Elisabeth Bjork reported a purchase of 10,000 shares of Rocket Pharmaceuticals common stock on January 2, 2026 at a price of $3.44 per share.

How many Rocket Pharmaceuticals (RCKT) shares does Elisabeth Bjork own after this Form 4?

Following the reported transaction, Elisabeth Bjork beneficially owned 50,000 shares of Rocket Pharmaceuticals common stock.

At what price were the Rocket Pharmaceuticals (RCKT) shares purchased in this Form 4?

The 10,000 Rocket Pharmaceuticals shares reported in the Form 4 were purchased at a price of $3.44 per share.

Does Elisabeth Bjork’s Rocket Pharmaceuticals share total include restricted stock units (RSUs)?

Yes. The filing states that her holdings include 30,000 restricted stock units (RSUs), which convert to common stock on a one-for-one basis.

When do Elisabeth Bjork’s restricted stock units in Rocket Pharmaceuticals vest?

The 30,000 RSUs in Rocket Pharmaceuticals are scheduled to vest in full on June 18, 2026, after which they convert into common shares.

Is Elisabeth Bjork a director or officer of Rocket Pharmaceuticals (RCKT)?

The Form 4 identifies Elisabeth Bjork as a director of Rocket Pharmaceuticals and indicates she is not an officer and not a 10% owner.